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ABSTRACT
Introduction Streptococcus pneumoniae (the 
pneumococcus) is commonly carried as a commensal 
bacterium in the nasopharynx but can cause life- 
threatening disease. Transmission occurs by human 
respiratory droplets and interruption of this process 
provides herd immunity. A 2017 WHO Consultation 
on Optimisation of pneumococcal conjugate vaccines 
(PCV) Impact highlighted a substantial research gap 
in investigating why the impact of PCV vaccines in 
low- income countries has been lower than expected. 
Malawi introduced the 13- valent PCV (PCV13) into 
the national Expanded Programme of Immunisations 
in 2011, using a 3+0 (3 primary +0 booster doses) 
schedule. With evidence of greater impact of a 
2+1 (2 primary +1 booster dose) schedule in other 
settings, including South Africa, Malawi’s National 
Immunisations Technical Advisory Group is seeking 
evidence of adequate superiority of a 2+1 schedule to 
inform vaccine policy.
Methods A pragmatic health centre- based evaluation 
comparing impact of a PCV13 schedule change 
from 3+0 to 2+1 in Blantyre district, Malawi. Twenty 
government health centres will be randomly selected, 
with ten implementing a 2+1 and 10 to continue 
with the 3+0 schedule. Health centres implementing 
3+0 will serve as the direct comparator in evaluating 
2+1 providing superior direct and indirect protection 
against pneumococcal carriage. Pneumococcal carriage 
surveys will evaluate carriage prevalence among 
children 15–24 months, randomised at household 
level, and schoolgoers 5–10 years of age, randomly 
selected from school registers. Carriage surveys 
will be conducted 18 and 33 months following 2+1 
implementation.
Analysis The primary endpoint is powered to detect 
an effect size of 50% reduction in vaccine serotype (VT) 
carriage among vaccinated children 15–24 months old, 
expecting a 14% and 7% VT carriage prevalence in the 
3+0 and 2+1 arms, respectively.
Ethics and dissemination The study has been approved 
by the Malawi College of Medicine Research Ethics 
Committee (COMREC; Ref: P05.19.2680), the University 
College London Research Ethics Committee (Ref: 
8603.002) and the University of Liverpool Research Ethics 
Committee (Ref: 5439). The results from this study will be 
actively disseminated through manuscript publications and 
conference presentations.
Trial registration number NCT04078997.
INTRODUCTION
Streptococcus pneumoniae, the pneumococcus, 
is commonly carried as a commensal bacte-
rium in the nasopharynx but can cause life- 
threatening disease. Infections due to the 
pneumococcus are estimated to be respon-
sible for approximately 300 000 deaths 
Strengths and limitations of this study
 ► The study is supported by more than 20 years of 
routine pneumococcal surveillance.
 ► The study design is both pragmatic and robust, of-
fering a methodology that is relevant to diverse set-
tings in the region.
 ► By engaging community, institutional and govern-
ment partners, we have optimised its relevance and 
increased the likelihood of community uptake.
 ► Limitations to this study include a risk of contam-
ination between clusters (ie, children receiving a 
2+1 vaccine schedule who reside in or relocate to 
a cluster implementing the 3+0 vaccine schedule or 
vice- versa).
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worldwide, with one- third of these occurring among chil-
dren under 5 years of age and with the greatest burden in 
low- and middle- income country settings.1 2
S. pneumoniae has almost 100 serotypes, with nasopharyn-
geal (NP) carriage as a prerequisite for the development of 
disease but also a key process for developing natural immu-
nity.3 Transmission occurs largely via human respiratory air 
droplets. With serotype- specific differences, carriage dura-
tion decreases with age, lasting from 2 weeks in adults up 
to 4 months among children.4 5 Pneumococcal carriage 
prevalence is age- dependent, peaking among children <5 
years. Pneumococcal carriage prevalence reported in sub- 
Sahara Africa are among the highest described; up to 28% 
among adults and in excess of 80% in children <5 years old, 
resulting in high transmission rates.6–14
In HICs, routine administration of pneumococcal 
conjugate vaccines (PCV) through the infant immuni-
sation schedule has contributed to a rapid decline of 
vaccine serotype invasive pneumococcal disease (VT- IPD) 
in both vaccinated and unvaccinated populations.15–23 
PCVs protect the vaccinated individual (direct protec-
tion) against pneumococcal disease and carriage. The 
resulting reduction in carriage also interrupts transmis-
sion from the vaccinated individual to the unvaccinated 
population (indirect protection). The resulting herd 
immunity effect has been a major contributor to the 
success of vaccination programmes.24–26 The added cost- 
effectiveness and vaccine impact gained through indirect 
protection have been key drivers of vaccination policy in 
these settings.27 28 PCV impact on pneumococcal carriage 
continues to be considered a viable endpoint in vaccine 
licensure evaluations.29
Studies undertaken prior to PCV introduction in The 
Gambia, Kenya, Mozambique, Malawi and South Africa 
reported VT carriage prevalence ranging from 28% 
to nearly 50% among children <5 years old.30–33 While 
PCV introduction in African countries has resulted in 
substantial direct effects in reducing risk of VT- IPD,34 
pneumonia and all- cause mortality35 among vaccinated 
children,10 11 36 the impact of PCV on VT carriage has 
been markedly less than that observed in HICs. Although 
Kenya,12 the Gambia,13 Mozambique14 and South Africa31 
have reported VT carriage reductions, prevalence remains 
higher than expected, and serotype replacement (ie, rise 
in non- VT carriage prevalence associated with decrease 
in VT carriage) is increasing.6 37 As the impact of PCV on 
carriage is considered an indicator of vaccine impact,29 
it remains uncertain whether PCV introduction in sub- 
Sahara Africa will achieve the sustained direct or indirect 
protection necessary to reduce pneumococcal carriage to 
levels sufficient to interrupt transmission and disease.38
Currently, WHO recommends the implementation 
of the PCV vaccine using either a 3+0 schedule (three 
primary doses, most commonly at 6, 10, and 14 weeks 
of age) or a 2+1 schedule (two primary infancy doses 
at 6 and 14 weeks of age and one booster at 9 months 
of age or after the first year of life). The WHO further 
recommends that the decision on which schedule to 
use be based on the epidemiology of disease in the local 
setting.39 While both schedules have been shown to be 
effective in reducing VT disease and VT carriage, there 
have been no direct comparisons of vaccine impact on 
carriage in a high burden setting.40
A 2017 WHO Technical Expert Consultation on 
Optimisation of PCV Impact highlighted a substantial 
research gap in investigating why the impact of PCV 
vaccines in low- income countries has been less than 
expected, underlining the need to define an optimal 
PCV vaccination schedule that will maximise their benefit 
in such settings.41 The PCV Review of Impact Evidence, 
commissioned to supplement the WHO Expert Consul-
tation, is a systematic review of available evidence on 
PCV effectiveness and impact on NP carriage, disease 
and mortality, as well as on PCV immune response. The 
review included evidence from research studies published 
between January 2010 and December 2016 recorded in 
14 databases. Those attending the 2017 WHO Technical 
Expert Consultation gave head- to- head studies of 2+1 vs 
3+0 vaccine schedules the greatest research priority.42 
Countries with a high pneumococcal disease and carriage 
burden, such as Malawi, could implement a 2+1 schedule 
quickly, with limited logistical or financial demands, 
providing a booster dose at the time of the first measles 
vaccine at 9 months of age.
Malawi introduced the 13- valent PCV (PCV13) into 
the national Expanded Programme of Immunisations 
(EPI) in November 2011, using a 3+0 schedule (6, 10 
and 14 weeks of age), with a three- dose catch- up vacci-
nation campaign among all infants <1 year of age. This 
introduction has been highly successful, with field studies 
showing an EPI vaccine coverage exceeding 90%.43 44 
Similar to other settings, vaccine introduction resulted 
in a~70% reduction in IPD among PCV- vaccinated chil-
dren34 and an estimated 35% fall in all- cause mortality.35 
However, high levels of residual VT carriage persist in 
Malawi among vaccinated children up to 8 years after the 
introduction of the vaccine.45 As presented by Lourenço 
et al46 a high force of infection in settings such as Malawi 
contribute significantly to a 3+0 schedule achieving only a 
short duration of VT carriage control in infants. Though 
a 2+1 schedule, as implemented in South Africa, may 
improve colonisation control, this remains unproven in 
other African settings such as Malawi.
In this context, the Malawi Ministry of Health (MoH) 
and the National Immunisations Technical Advisory Group 
are now seeking evidence of adequate superiority of a 2+1 
vaccine schedule to inform a change to Malawi’s current EPI 
schedule. To this aim, a pragmatic health centre- based evalu-
ation comparing the current 3+0 schedule to a 2+1 schedule 
will be implemented in Blantyre District, southern Malawi. 
Two pneumococcal carriage surveys, conducted 18 and 33 
months following the implementation of the 2+1 schedule, 
will have the objective of comparing the effect of the two 
schedules against carriage reduction among otherwise- 
healthy children and evaluate their potential to enhance 
herd immunity.
 on A









pen: first published as 10.1136/bm








The study is a pragmatic health centre- based randomised 
evaluation of the direct effect of a 2+1 PCV13 vaccine 
schedule on pneumococcal carriage in vaccinated infants 
and the indirect effect on non- vaccine eligible children 
and high- risk adults.
Study setting
The study will be conducted in Blantyre district, southern 
Malawi. The District is 240 km2. Healthcare is delivered 
through a network of private and government hospitals 
and 28 government primary health centres, where EPI 
vaccinations are administered. Queen Elizabeth Central 
Hospital (QECH) is the government referral hospital 
providing free medical care to the 1.3 million urban, peri-
urban and rural residents of Blantyre District. Children 
<5 years account for 16% of the total population.47 Health 
centres cover a fixed geographic area (here referred to as 
‘clusters’), and study sampling will be undertaken within 
these clusters (figure 1).
Study questions
We will investigate whether a 2+1 PCV13 vaccination 
schedule (two primary doses at 6 and 14 weeks of age +1 
booster dose at 9 months of age), compared with the 
current 3+0 schedule (three primary doses at 6, 10 and 
14 weeks of age with no booster), is superior in reducing 
VT carriage prevalence among vaccinated children and, 
consequently, creating a superior herd effect among older 
children and HIV- infected adults. To assess the effect of 
a district- wide change from 3+0 to 2+1, this study will 
address two specific research questions: First, will a 2+1 
schedule provide enduring vaccine- induced protection 
against pneumococcal VT carriage into the second year 
of life? Second, will the 2+1 vaccine schedule generate 
stronger herd protection and result in decreased VT 
carriage in older children and unvaccinated high- risk 
adults in the general population?
Primary objective
The primary objective of the study is to evaluate the direct 
effect of a 2+1 PCV13 vaccination schedule on VT pneu-
mococcal carriage among children aged 15–24 months, 
3 years after introducing the 2+1 schedule. This objective 
will answer the question of whether the 2+1 schedule 
induces a more enduring direct protection against 
pneumococcal VT carriage into the second year of life, 
compared with that observed with a 3+0 schedule.
Figure 1 Map of Blantyre district with borders of health centre catchment areas. Red crosses (+) indicate location of health 
centres offering EPI vaccination. Areas shaded in green are non- inhabited (incl. mountains, industrial zones and other regions 
administratively declared not for habitation). EPI, Expanded Programme of Immunisations.
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Secondary objectives
The secondary objectives of the study are to evaluate, 
3 years after introducing the 2+1 schedule, (1) the indirect 
effect of a 2+1 schedule on VT pneumococcal carriage 
among children aged 5–10 years (PCV age- ineligible at 
time of implementing the 2+1 schedule); (2) the indirect 
effect of a 2+1 vaccination schedule on VT pneumococcal 
carriage among HIV- infected adults 18–40 years old and 
on antiretroviral therapy (ART).
To address these questions, the Malawi MoH and Blan-
tyre District Health Office (DHO) will randomly select 
10 health centres (among a total 28 in Blantyre District) 
in which the routine PCV13 schedule will be switched 
to a 2+1 schedule. An additional 10 health centres will 
be randomly selected to continue with the current 3+0 
schedule but will serve as the direct comparator in evalu-
ating the effectiveness of the 2+1 schedule.
A pragmatic study design
This switch to a 2+1 schedule is an initiative led by the 
MoH and will be implemented within the scope of the 
routine EPI programme, subject to EPI standard proce-
dures for delivery, monitoring and performance assess-
ment. Implementation of all vaccination activities will be 
implemented, as per routine practices, by MoH EPI vacci-
nators through the routine EPI programme. The MoH 
will monitor completeness of dosing following standard 
reporting practices within the scope of the EPI. Routine 
study activities throughout the duration of the 3- year study 
period will include research nurses providing support 
and guidance to the EPI vaccination teams through 
weekly site visits. In addition, research enumerators will 
monitor patient- retained health passports of a represen-
tative sample population of vaccinees to confirm they 
are receiving the proper vaccine schedule (2+1 or 3+0) 
assigned to the catchment population of their respective 
health centre.
The pragmatic design of this study has been assessed 
through the tool The PRagmatic- Explanatory Continuum 
Indicator Summary 2 (PRECIS-2).48 This tool was devel-
oped to help trialists make design decisions consistent with 
the intended purpose of their trial. To facilitate domain 
discussion and consensus, PRECIS-2 assesses the prag-
matic design through nine domains—eligibility criteria, 
recruitment, setting, organisation, flexibility (delivery), 
flexibility (adherence), follow- up, primary outcome and 
primary analysis—scored from 1 (very explanatory) to 
5 (very pragmatic). The report from this tool is in the 
format of a wheel (figure 2). Results (mean score: 4.4 
and range: 3–5) supports that this is largely a pragmatic 
randomised study undertaken in the ‘real world’ and with 
usual care and is intended to help support a decision on 
whether to deliver an intervention.
3+1 schedule during early period of initiation
To ensure the 2+1 schedule is implemented efficiently, 
and to limit the risk of confusion during the transition to 
the 2+1 schedule (including not deferring PCV13 vaccina-
tion to a later visit), a 3+1 schedule will be implemented 
during the first several months at health centres imple-
menting the 2+1 schedule. At these health centres, chil-
dren who have received either their 10 weeks or 14 weeks 
PCV13 dose before 2+1 implementation will receive a dose 
at their 14 weeks (third dose PCV13) and their 40 weeks 
(fourth dose PCV13). Approximately 6 months after 2+1 
implementation, all first- contact vaccine visits (post 2+1 
implementation) will be for the scheduled visit at 6 weeks 
of age and the 3+1 schedule will no longer be required.
Carriage surveys
The study will include two cross- sectional carriage 
surveys, implemented 18 and 33 months after the switch 
to 2+1. Carriage surveys will be conducted using a well- 
established methodology implemented extensively in 
Figure 2 The PRagmatic- Explanatory Continuum Indicator Summary 2 wheel with study- specific scores.
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the setting,45 46 allowing comparability of study results 
to previous carriage surveys conducted in the area. The 
sampling frame is illustrated in figure 3.
Sampling will include:
1. Children 15–24 months of age, PCV13- vaccinated 
(confirmed by reviewing patient- retained health 
passports) with either the 2+1 or the 3+0 schedule. 
Evaluation within this age group will allow us to eval-
uate for our primary objective, evaluating the direct 
effect of vaccination on carriage. Within each of the 
catchment areas of the 20 participating health cen-
tres, we will conduct a random walk method to sys-
tematically identify households with eligible children. 
A ‘egg and yolk’ strategy will be applied, defining two 
geographic sampling perimeters around each health 
centre. Sampling will prioritise those living within the 
geographic perimeter closest to the health centre. In 
the event that recruitment targets are not met, sam-
pling will move into the second geographic perimeter. 
This strategy will maximise the likelihood of recruit-
ing children who have received their vaccines at the 
selected health centre, minimising recruitment from 
buffer zonal borders and therefore minimising risk of 
contamination (ie, recruitment of children receiving 
a PCV13 vaccine schedule different than the schedule 
assigned to the child’s local health centre).
2. Children 5–10 years of age, PCV13- vaccinated with the 
3+0 schedule. These children, having received PCV13 
at infancy, will be recruited from government schools. 
Evaluation within this age group will allow us to eval-
uate for a secondary objective, evaluating the indirect 
effect of a 2+1 schedule on VT pneumococcal carriage 
among children aged 5–10 years, the majority of whom 
received PCV13 infancy EPI vaccination using a 3+0 
schedule. Six schools will be selected, three located 
centrally in each of the 3+0 clusters and the 2+1 clus-
ters. Children will be chosen at random from school 
registers. This component will allow the evaluation of 
indirect effects of the 2+1 compared with 3+0 schedule 
among children with waning vaccine- induced immu-
nity.
3. Adults 18–40 years of age, HIV- infected on ART and 
PCV13- unvaccinated. Evaluation within group will al-
low us to achieve the secondary objective of evaluating 
the indirect effect of a 2+1 schedule on VT pneumo-
coccal carriage among HIV- infected adults (18–40 
years) on ART, a population at high risk of pneumo-
coccal disease. Participants will be recruited from the 
QECH, Lighthouse ART Clinic in Blantyre.
Safety
To assess the differential effects of 3 vs 2 primary vaccine 
doses in the first year of life, an additional carriage survey 
will be implemented at health centres approximately 9 
months after 2+1 implementation. A convenience sample 
of children aged 9 months will be recruited at health 
centres providing either the 2+1 or 3+0 schedule. This 
will allow an evaluation of carriage prevalence among 
children receiving 3 (according to the 3+0 schedule) vs 2 
(according to the 2+1 schedule and presenting for their 
booster dose) primary doses. Additionally, this additional 
carriage survey will contribute to evaluating the coverage 
of the 2+1 vaccination schedule and the proportion of 
children receiving all three PCV13 doses at health centres 
providing the 2+1 schedule.
Inclusion and exclusion criteria
Inclusion criteria for all individuals recruited includes 
permanent resident in Blantyre District. Among chil-
dren 15–24 months of age (assigned to either 2+1 or 
3+0 schedule), inclusion criteria additionally include: 
aged between 15 and 24 months, parent/legal guardian 
providing written informed consent, evidence (recorded 
in health passport) of having received a full schedule 
Figure 3 Carriage surveillance sampling frame black dashed vertical line separates primary (left of dashed line) from 
secondary study objectives. ART, antiretroviral; M, months; PCV, pneumococcal conjugate; QECH, Queen Elizabeth Central 
Hospital.
 on A









pen: first published as 10.1136/bm




6 Swarthout TD, et al. BMJ Open 2021;11:e050312. doi:10.1136/bmjopen-2021-050312
Open access 
of PCV13. Among children 5–10 years of age, inclusion 
criteria include: aged between 5–10 years, parent/legal 
guardian providing written informed consent, providing 
written informed assent (if the child is aged ≥8), and 
either verbal or documented evidence of having received 
PCV13. Among adults, inclusion criteria include: aged 
18–40 years, providing written informed consent, and 
being HIV- infected and receiving ART.
Among children 9 months of age, recruited as part of 
the safety component, inclusion criteria include: aged 
9 months, parent/legal guardian providing written 
informed consent, and evidence (recorded in health 
passport) of having received either a full 3+0 PCV13 
vaccine schedule (health centres implementing 3+0) or 
both primary doses of PCV13 at approximately 6 and 14 
weeks of age (health centres implementing 2+1).
Exclusion criteria for all screened individuals include 
receiving TB treatment at time of screening, hospital-
isation for pneumonia within 14 days prior to study 
screening and terminal illness. Exclusion criteria for all 
children include parental/legal guardian not providing 
consent, not providing assent (for children aged ≥8 
years), having received antibiotic treatment within 14 
days prior to study screening. Exclusion criteria for adults 
include not providing written informed consent or prior 
vaccination with a pneumococcal vaccine.
Intervention
The intervention will consist of two carriage surveys 
conducted 18 and 33 months after the 10 randomised 
health centres switch from a 3+0 to a 2+1 PCV13 schedule. 
In both surveys, a single NP swab will be collected from 
each participant. Following previously described WHO- 
recommended procedures,45 49 these will be collected and 
taken to the Malawi- Liverpool- Wellcome Trust Clinical 
Research Programme laboratory in Blantyre for the isola-
tion and characterisation of S. pneumoniae. VT pneumo-
coccal carriage will be serotyped by latex agglutination. 
Samples from participants with confirmed pneumococcal 
carriage will be sent to the UK for assessment of multiple 
serotype carriage (genomic microarray) and for whole 
genome sequencing.
Expected outcomes
The primary endpoint of this study will be the difference 
in VT pneumococcal carriage prevalence among children 
aged 15–24 months, comparing those vaccinated with 
PCV13 in either a 2+1 or 3+0 schedule, 3 years after imple-
menting the switch to a 2+1 schedule. Additionally, the 
study will evaluate four secondary outcomes: (1) differ-
ence in VT carriage prevalence among children 5–10 
years old, 18 months and 33 months after 2+1 implemen-
tation, (2) VT carriage prevalence among HIV- infected 
adults aged 18–40 years and receiving ART at the time of 
sampling, (3) VT carriage prevalence among infants aged 
9 months, who will have received three primary doses 
(3+0 health centres) or two primary doses (2+1 health 
centres) prior to the booster dose, 9 months after the 
implementation of the 2+1 schedule and (4) prevalence 
of multiple serotype carriage, 18 and 33 months after 2+1 
implementation
Patient and public involvement statement
Prior to development of the protocol, key stakeholders 
were informed of the study, including the study sites (ie, 
selected health centres) and their surrounding communi-
ties (ie, catchment areas), the DHO, MoH and the Ministry 
of Education. We actively sought and incorporated input 
from these stakeholders into the study objectives and overall 
design. Community sensitisation will be further strength-
ened through a community advisory board.
Statistical methods
Study power and sample size calculation
The primary endpoint is powered to detect an effect size 
of 50% reduction in VT carriage, expecting a 14% and 
7% VT carriage prevalence among vaccinated children 
15–24 months old in the 3+0 and 2+1 arms, respectively. 
Sample sizes were calculated based on a power of 80% 
and a statistical significance of 0.05. The calculations 
accounted for household similarities using an intraclass 
correlation (ICC) of 0.005 (based on previous experience 
in this setting) and adjusted for a design effect (depen-
dent on both ICC and cluster size.) of 1.21. Minimum 
sample sizes needed to achieve the necessary power 
under these assumptions are shown in table 1.
To assess the primary and secondary endpoints (1) One 
child 15–24 months of age (2+1 or 3+0) will be recruited 
from each of 40 households randomly selected within 
each of the 20 clusters. This is a total 800 vaccinated chil-
dren per survey (1600 total for two surveys). (2) A total 
of 125 children will be recruited from each of the six 
schools per survey. This is a total 750 children per survey 
(1500 total). (3) A total of 1200 HIV- infected adults will 
be recruited from the QECH ART Clinic over the course 
of the 3- year study period. (4) A total of 800 children 
9 months of age will be recruited from the vaccination 
centres 9 months after schedule change (800 total).
Data collection, management and anonymisation procedures
Demographic data and relevant medical history will 
be collected using password- protected electronic data 
capturing. Each participant will be assigned a unique partic-
ipant identification number (PID) at recruitment. This PID 
will be used in all datasheets and files, and will be linked 
to the laboratory data, hence, only anonymised data will be 
used for the analysis. Fully anonymised data will be uploaded 
daily to a secured on- site server, which is backed up daily to 
both local and off- site facilities. A logbook containing iden-
tifiable information (including name) will be kept separate 
in a secured location by an authorised member of the study 
team and will only be accessed by authorised study members. 
This will allow the study team to recover any missing epide-
miological information at a later date (eg, missing vaccina-
tion dates) and to facilitate any participants who choose to 
withdraw consent at any time.
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Statistical analyses
Continuous variables will be summarised by means and 
SD, or medians and IQRs if the distribution exhibits skew. 
Categorical variables will be summarised by frequency 
distributions. Direct effects of the PCV13 schedule change 
on VT carriage will be ascertained by comparing carriage 
prevalence in children aged 15–24 months residing in the 
recruitment clusters of health centres randomised to the 
2+1 schedule and those in recruitment clusters of health 
centres randomised to the 3+0 schedule. Indirect effects 
will be evidenced by comparing children in the recruit-
ment clusters of health centres randomised to the 3+0 
schedule among older children (5–10 years) and HIV 
+adults. Additionally, data obtained in this study will be 
compared with those obtained from previous carriage 
surveys to ascertain any changes in VT carriage preva-
lence before and after the PVC13 schedule change. Statis-
tical tests will be selected depending on the distribution 
patterns of the data. Potential confounders and sources 
of interaction (including age, gender and health centre) 
will be identified by testing the association between vari-
ables and VT carriage and included in the multivari-
able models when p<0.1. Sensitivity analyses will include 
assessing impact of (1) receiving only one, only two or all 
three doses PCV; (2) having document- confirmed PCV 
vaccination or (3) schedule adherence to within 2 weeks 




The study has been approved by the Malawi College of 
Medicine Research Ethics Committee (COMREC; Ref: 
P05.19.2680), the University College London Research 
Ethics Committee (Ref: 8603.002) and the University of 
Liverpool Research Ethics Committee (Ref: 5439).
Data monitoring external advisory group
The implementation of the study protocol will be reviewed 
and monitored by an External Advisory Group, providing 
oversight of the study activities and advise the study 
team at the time of the interim and final analyses. The 
group will include experts from the University of Malawi, 
College of Medicine, the London School of Hygiene & 
Tropical Medicine and the Medical Research Council.
Interim analysis and changes to public health policy
On completion of the first carriage survey, an interim 
analysis will be implemented using data obtained on 
the VT carriage prevalence among vaccinated children 
15–24 months of age. These results will be used to assess 
possible adaptation of the second community carriage 
survey. Three possible scenarios are considered: (1) If 
convincing evidence of major change in carriage preva-
lence is demonstrated, immediate action will be discussed 
with the MoH to move to change the schedule and adapt 
year-3 sampling; (2) If no major change in carriage preva-
lence is identified, the study will continue as planned; (3) 
If carriage prevalence has fallen by more than 30% but 
does not meet the primary threshold of 50%, the second 
carriage survey will be brought forward by 6 months. 
Decisions will be reached in consensus between investiga-
tors, the Expert Advisory group, and the MoH.
Informed consent process
The study will only recruit children whose parents/legal 
guardians have the capacity to provide informed consent 
or, in the case of adults, are capable of giving consent. Chil-
dren who are minors but ≥8 years of age will be required 
to provide informed assent, in addition to parents/legal 
guardians providing informed consent. Participants will 
receive both verbal and written information about the 
study and will be given the opportunity to ask questions 
and express their doubts and concerns before accepting 
Table 1 Sample size estimations
N per cluster ICC p1 p2 Power Alpha DE N per arm Clusters, per arm Clusters, total N total
40 0.005 0.14 0.07 0.8 0.05 1.20 358 9 18 720
40 0.005 0.14 0.07 0.8 0.05 1.21 400 10 20 800
45 0.005 0.14 0.07 0.8 0.05 1.22 366 9 18 810
50 0.005 0.14 0.07 0.8 0.05 1.25 373 8 16 800
55 0.005 0.14 0.07 0.8 0.05 1.27 381 7 14 770
60 0.005 0.14 0.07 0.8 0.05 1.30 388 7 14 840
40 0.01 0.14 0.07 0.8 0.05 1.39 417 11 22 880
45 0.01 0.14 0.07 0.8 0.05 1.44 432 10 20 900
50 0.01 0.14 0.07 0.8 0.05 1.49 447 9 18 900
55 0.01 0.14 0.07 0.8 0.05 1.54 462 9 18 990
60 0.01 0.14 0.07 0.8 0.05 1.59 477 8 16 960
40 0.015 0.14 0.07 0.8 0.05 1.59 475 12 24 960
DE, design effect; ICC, intraclass correlation.
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to take part. They will also be given time to reflect before 
they come to a decision. An informed consent and/or 
assent form will be signed and dated by the participant 
and a member of the research team. The participant will 
keep a copy of the document, and a second one will be 
kept in the study file with the Principal Investigator based 
in Blantyre, Malawi. Participants will be informed of their 
right to withdraw consent at any point until study ends 
without the need to provide a reason and without penalty.
DISSEMINATION POLICY AND PLANS
Study results will be shared with local stakeholders and 
published in peer- reviewed journals. Partial results and 
interim analyses will be shared with the Malawi MoH and 
other relevant policymakers and decision- making stake-
holders. Partial and final findings will be presented at 
relevant international conferences and meetings. Copies 
of all published materials and reports will be shared with 
the research ethics committees and collaborators. We 
will return to the community partners and work with the 
community advisory board to report and further dissemi-
nate our results into those communities where we worked.
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